82-LB: Total Costs of Care in Patients with T2D and Cardiovascular Disease: A Comparative Cohort Study (OFFSET)

Introduction: Approximately one third of patients with T2D have cardiovascular disease (CVD). The 2019 ESC and ADA/EASD guidelines recommend glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as either first- or second-line antidiabetic medication in these patients. We aimed to investigate the budget implications of treating patients with CVD with GLP-1 RAs rather than standard of care (SoC). Methods: GLP-1 RA-naive adults (≥ 18 years old) with T2D in the IBM MarketScan® database who had a claim for an antidiabetic medication (index date) within 6 months after their first hospitalization for CVD were included. Costs of care per month over the 365 days post-index were compared for those who initiated a GLP-1 RA post-hospitalization versus those with a claim for any other antidiabetic medication (SoC). Results: Prior to hospitalization, total costs were similar for the two groups. After hospitalization and treatment initiation, adjusted mean total costs were lower, although not significantly, for patients receiving a GLP-1 RA compared with SoC. This was driven by significantly lower inpatient and outpatient costs and significantly higher drug costs (Figure). Conclusions: These findings suggest that the added cost of treating patients with T2D with GLP-1 RAs is offset by significantly lower inpatient and outpatient care costs after CVD hospitalization, resulting in budget neutrality against SoC. Disclosure M. Evans: Consultant; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Novo Nordisk A/S. A. Chandramouli: Employee; Self; Novo Nordisk. M. Faurby: Employee; Self; Novo Nordisk A/S. K. S. Matthiessen: Employee; Self; Novo Nordisk A/S. P. Mogensen: Consultant; Self; Novo Nordisk. S. Verma: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, Sanofi, Research Support; Self; AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim (Canada) Ltd., Eli Lilly and Company, EOCI Pharmacomm Ltd., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, Sanofi, Sun Pharmaceutical Industries Ltd., Toronto Knowledge Translation Working Group. Funding Novo Nordisk A/S